IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
Retrieved on:
Friday, September 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Monalizumab, CT, Incidence, Prednisone, European Society for Medical Oncology, Oleclumab, Safety, Warning, Carboplatin, Breathe Me, Doctor of Philosophy, Patient, Infection, ESMO, Company, Ballistic missile, Risk, HIV disease progression rates, Neoplasm, Phase, AEGEAN, ORR, CRT, HR, Solution, MD, Death, Progression-free survival, NSCLC, Hope, Etoposide, Cisplatin, Creatinine, Lung cancer, Pneumonitis, Radiation, Administration, AstraZeneca, PFS, Yale Cancer Center, Oncology, Congress, Pharmaceutical industry, Medical imaging, Medical device, Vaccine, Stage III NSCLC, COAST, PACIFIC-R, IMFINZI® (durvalumab), Oleclumab, Monalizumab, AstraZeneca Support Programs, AstraZeneca in lung cancer, AstraZeneca in immunotherapy, AstraZeneca in oncology, AstraZeneca, STAGE III NSCLC, COAST, PACIFIC-R, IMFINZI® (DURVALUMAB), OLECLUMAB, MONALIZUMAB, ASTRAZENECA SUPPORT PROGRAMS, ASTRAZENECA IN LUNG CANCER, ASTRAZENECA IN IMMUNOTHERAPY, ASTRAZENECA IN ONCOLOGY, ASTRAZENECA
The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.
Key Points:
- The Company is also testing novel combinations with IMFINZI in the Phase II NeoCOAST trial in the neoadjuvant early-stage setting.
- IMFINZI is indicated for the treatment of adult patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
- Sequential vs Concurrent Chemoradiation for Stage III NonSmall Cell Lung Cancer: Randomized Phase III Trial RTOG 9410.
- Current Standards and Clinical Trials in Systemic Therapy for Stage III Lung Cancer: What is New?